2008
DOI: 10.1016/j.ijpharm.2008.07.012
|View full text |Cite
|
Sign up to set email alerts
|

Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
97
0

Year Published

2011
2011
2020
2020

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 162 publications
(99 citation statements)
references
References 37 publications
1
97
0
Order By: Relevance
“…95 Epidermal growth factor receptor (EGFR) is an important anti-cancer therapy target that is applicable to many cancer types. 99 Anti-EGFR antibodies and EGF have been conjugated onto liposomes, lipid nanoparticles, chitosan particles and magnetic particles to target cancer cells over-expressing EGFR and the delivery of anticancer drugs or siRNA. In vitro uptake and cytotoxicity of EGF-GemC18-NPs realised with different human breast adenocarcinoma cell lines showed a correlation between EGFR density on the cell surface and cell uptake and toxicity.…”
Section: Lipophilic Prodrugsmentioning
confidence: 99%
“…95 Epidermal growth factor receptor (EGFR) is an important anti-cancer therapy target that is applicable to many cancer types. 99 Anti-EGFR antibodies and EGF have been conjugated onto liposomes, lipid nanoparticles, chitosan particles and magnetic particles to target cancer cells over-expressing EGFR and the delivery of anticancer drugs or siRNA. In vitro uptake and cytotoxicity of EGF-GemC18-NPs realised with different human breast adenocarcinoma cell lines showed a correlation between EGFR density on the cell surface and cell uptake and toxicity.…”
Section: Lipophilic Prodrugsmentioning
confidence: 99%
“…GE11 is a novel peptide first reported on by Li et al in 2005, 18 and its high affinity for certain EGFR-positive tumor cells has been verified ex vitro and in vivo. 19,20 However, the potential for use of this peptide as a targeting ligand to achieve targeted drug delivery to tumors, especially NSCLC, has not as yet been reported.…”
Section: Introductionmentioning
confidence: 99%
“…A variety of molecules, including peptides, antibodies, proteins, charged molecules, and some low-molecular weight ligands, such as folate, and nucleic acid-based aptamers, have been studied in conjunction with liposomes for enhanced anticancer treatment. [75][76][77][78] Enhanced tumor targeting can also be attained via exploiting specific features in the tumor microenvironment such as lowered extracellular pH 79) and an altered pattern of extracellular proteins. 80) For example, Zhu et al 80) exploited elevated levels of matrix metalloprotease 2 in the tumor microenvironment to improve cancer cell-specific delivery of loaded drugs via conjugating the anti-nucleosome monoclonal antibody (mAb 2C5) to PEGylated liposomes.…”
Section: Current Applications Of Liposomesmentioning
confidence: 99%